OLIPASS Corporation (244460) Stock Overview

OLIPASS Corporation, together with its subsidiaries, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes, SCN9A for pain; PCSK9 for hyper cholesterolemia; VEGF; HIF-1a; Dystrophin; and PTP1B products. OLIPASS Corporation was founded in 2006 and is headquartered in Yongin, south Korea.